US-LISTED SHARES OF TEVA PHARMACEUTICAL UP 3.5% PREMARKET AFTER CO'S IMMUNE DISORDER DRUG MEETS MAIN GOAL IN MID-STAGE TRIAL

Reuters · 3d ago

Please log in to view news